BioSenic provides support to forthcoming European conference on graft-versus-host disease

Mont-Saint-Guibert, Belgium, January 31, 2024, 7.00 am CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it will attend and support the upcoming GvHGvL Meeting on 13-15 March, 2024 at University Hospital Regensburg, a biannual conference to lead scientific exchange around graft-versus-host disease (GvHD).

GvHD can result from transplanting bone marrow or stem cells from a donor to a patient. BioSenic is planning a Phase 3 study of its first-in-class oral arsenic trioxide (OATO) therapy in patients with chronic GvHD (cGvHD), a focus area for the company. The trial will test OATO as a first-line therapy for cGvHD and will begin enrolling the first of about 150 patients over three continents this year. After consulting several clinicians with extensive cGvHD experience in order to develop the protocol for its pivotal Phase 3 study in cGvHD, BioSenic decided to provide support for the biannual meeting, which is organized and hosted by the University Hospital Regensburg in Regensburg, Germany.

BioSenic’s Chief Operating Officer and Chief Scientific Officer Carole Nicco, PhD, HDR and Chief Medical Officer Lieven Huysse, MD will attend the congress, focusing respectively on the biomarkers in cGvHD and fine-tuning of the outcome criteria for the upcoming cGvHD Phase 3 study. In addition, the pair will hold further discussions with international key opinion leaders in attendance.

Lieven Huysse, said: “This is an excellent opportunity for us to meet important key opinion leaders in the GvHD field, as we finalize the protocol of our state-of-the-art clinical study. We understand how crucial it is to select the most appropriate criteria if we are to move toward a confirmatory outcome for the use of OATO as a first-line therapy, in addition to the standard of care. We are looking forward to learning from leaders in the GvHD field as we concentrate all our efforts on getting the Phase 3 trial up and running.”

Carole Nicco adds: " We have learned from ATO’s mechanisms of action that it could be a very specific and novel type of immunomodulator. We now have a patent pending on biomarkers that allow us to follow the efficacy of treatment in cGvHD. We will focus on this aspect in the Phase 3 trial and ensure that we follow the effect of our treatment using the best possible biomarkers, which happens to be one of the very interesting sessions planned for GvH-GvL Meeting. I can't wait for detailed discussions with other experts in order to reach a consensus for the best-suited set of biomarkers we can add to the companion diagnostics we have already identified."